Cargando…
New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
Atopic dermatitis (AD) is a chronic cutaneous inflammatory disorder, characterized by skin barrier disruption. Dermacare is a new cosmetic formulation, which enhances moisturization, reinforces and repairs the skin barrier, and prevents cutaneous microbiota imbalance. To demonstrate its safety and e...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406490/ https://www.ncbi.nlm.nih.gov/pubmed/30700045 http://dx.doi.org/10.3390/children6020017 |
_version_ | 1783401316237705216 |
---|---|
author | de Lucas, Raúl García-Millán, Cristina Pérez-Davó, Azahara Moreno, Esther Redondo, Pedro |
author_facet | de Lucas, Raúl García-Millán, Cristina Pérez-Davó, Azahara Moreno, Esther Redondo, Pedro |
author_sort | de Lucas, Raúl |
collection | PubMed |
description | Atopic dermatitis (AD) is a chronic cutaneous inflammatory disorder, characterized by skin barrier disruption. Dermacare is a new cosmetic formulation, which enhances moisturization, reinforces and repairs the skin barrier, and prevents cutaneous microbiota imbalance. To demonstrate its safety and efficacy, a prospective, open-label, and multicenter study was carried out on patients diagnosed with mild to moderate AD. Transepidermal water loss (TEWL), clinical severity, Desquamation Index, Patient/Investigator Global Assessments, quality of life index, and tolerance were assessed. Adverse events were recorded. Daily application of the new treatment was well tolerated, and adverse events were absent. After 14 days, TEWL showed a 36.7% significant decrease (p = 0.035). At the end of the 28-day treatment, the Desquamation Index showed a reduction in 70% of patients; Eczema Area and Severity Index were reduced by 70.4% (p = 0.002); and skin irritation showed a significant reduction (p = 0.024). Likewise, Patient and Investigator Global Assessments reported a significant improvement in conditions and an overall global worsening when patients restarted their normal treatment. Parent’s Index of Quality of Life Index significantly increased by 36.4% (p < 0.05) with Dermacare. In conclusion, a regular use of this new formulation can reduce the risk of relapse and extend the steroid-free treatment periods. |
format | Online Article Text |
id | pubmed-6406490 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64064902019-03-13 New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis de Lucas, Raúl García-Millán, Cristina Pérez-Davó, Azahara Moreno, Esther Redondo, Pedro Children (Basel) Communication Atopic dermatitis (AD) is a chronic cutaneous inflammatory disorder, characterized by skin barrier disruption. Dermacare is a new cosmetic formulation, which enhances moisturization, reinforces and repairs the skin barrier, and prevents cutaneous microbiota imbalance. To demonstrate its safety and efficacy, a prospective, open-label, and multicenter study was carried out on patients diagnosed with mild to moderate AD. Transepidermal water loss (TEWL), clinical severity, Desquamation Index, Patient/Investigator Global Assessments, quality of life index, and tolerance were assessed. Adverse events were recorded. Daily application of the new treatment was well tolerated, and adverse events were absent. After 14 days, TEWL showed a 36.7% significant decrease (p = 0.035). At the end of the 28-day treatment, the Desquamation Index showed a reduction in 70% of patients; Eczema Area and Severity Index were reduced by 70.4% (p = 0.002); and skin irritation showed a significant reduction (p = 0.024). Likewise, Patient and Investigator Global Assessments reported a significant improvement in conditions and an overall global worsening when patients restarted their normal treatment. Parent’s Index of Quality of Life Index significantly increased by 36.4% (p < 0.05) with Dermacare. In conclusion, a regular use of this new formulation can reduce the risk of relapse and extend the steroid-free treatment periods. MDPI 2019-01-29 /pmc/articles/PMC6406490/ /pubmed/30700045 http://dx.doi.org/10.3390/children6020017 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication de Lucas, Raúl García-Millán, Cristina Pérez-Davó, Azahara Moreno, Esther Redondo, Pedro New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis |
title | New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis |
title_full | New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis |
title_fullStr | New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis |
title_full_unstemmed | New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis |
title_short | New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis |
title_sort | new cosmetic formulation for the treatment of mild to moderate infantile atopic dermatitis |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406490/ https://www.ncbi.nlm.nih.gov/pubmed/30700045 http://dx.doi.org/10.3390/children6020017 |
work_keys_str_mv | AT delucasraul newcosmeticformulationforthetreatmentofmildtomoderateinfantileatopicdermatitis AT garciamillancristina newcosmeticformulationforthetreatmentofmildtomoderateinfantileatopicdermatitis AT perezdavoazahara newcosmeticformulationforthetreatmentofmildtomoderateinfantileatopicdermatitis AT morenoesther newcosmeticformulationforthetreatmentofmildtomoderateinfantileatopicdermatitis AT redondopedro newcosmeticformulationforthetreatmentofmildtomoderateinfantileatopicdermatitis |